Exact Sciences Co. (NASDAQ:EXAS) Shares Sold by Global Retirement Partners LLC

Global Retirement Partners LLC reduced its position in Exact Sciences Co. (NASDAQ:EXAS) by 3.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,379 shares of the medical research company’s stock after selling 340 shares during the period. Global Retirement Partners LLC’s holdings in Exact Sciences were worth $471,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Huntington National Bank increased its holdings in Exact Sciences by 838.1% in the third quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock valued at $27,000 after buying an additional 352 shares in the last quarter. RPg Family Wealth Advisory LLC acquired a new stake in shares of Exact Sciences during the 3rd quarter valued at about $34,000. Capital Performance Advisors LLP purchased a new position in shares of Exact Sciences in the 3rd quarter valued at about $35,000. Asset Planning Inc acquired a new position in Exact Sciences in the 4th quarter worth about $40,000. Finally, Modus Advisors LLC purchased a new position in Exact Sciences during the fourth quarter worth approximately $43,000. 88.82% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

EXAS has been the topic of a number of recent analyst reports. Jefferies Financial Group increased their target price on Exact Sciences from $84.00 to $85.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. Evercore ISI decreased their price objective on shares of Exact Sciences from $80.00 to $60.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. Stifel Nicolaus cut their target price on shares of Exact Sciences from $82.00 to $67.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Robert W. Baird decreased their price target on shares of Exact Sciences from $70.00 to $67.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. Finally, Benchmark reiterated a “buy” rating and set a $65.00 price objective on shares of Exact Sciences in a research note on Monday, January 13th. One investment analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $72.06.

Exact Sciences Price Performance

Exact Sciences stock opened at $49.26 on Monday. The company has a current ratio of 2.15, a quick ratio of 1.93 and a debt-to-equity ratio of 0.97. The company has a 50-day moving average price of $54.91 and a 200 day moving average price of $60.04. Exact Sciences Co. has a 12-month low of $40.62 and a 12-month high of $79.62. The stock has a market cap of $9.15 billion, a P/E ratio of -8.84 and a beta of 1.24.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.23. The firm had revenue of $713.42 million for the quarter, compared to analyst estimates of $701.45 million. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. Sell-side analysts anticipate that Exact Sciences Co. will post -0.58 earnings per share for the current year.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.